Consolidated Balance Sheets $ in Thousands	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Current assets:
Cash and cash equivalents	$ 9,201	$ 6,602
Restricted cash	4	4
Prepaid expenses and other current assets	767	177
Total current assets	9,972	6,783
Property, equipment and leasehold improvements, net	66	73
Restricted cash - non current	110	110
Operating lease right-of-use assets	1,142	1,211
Prepaid clinical trial expenses	1,122	1,122
Other assets	22	26
Total assets	12,434	9,325
Current liabilities:
Accounts payable	988	942
Operating lease liabilities	302	294
Accrued expenses	581	1,427
Total current liabilities	1,871	2,663
Other liabilities	59	59
Operating lease liabilities - non current	944	1,020
Total liabilities	2,874	3,742
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 16,666,667 shares; 2,571,553 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at March 31, 2020; 550,736 shares issued and outstanding, including 6,886 shares of unvested restricted stock, at December 31, 2019	2	2
Additional paid-in capital	231,132	224,741
Accumulated deficit	(221,574)	(219,160)
Total stockholders’ equity	9,560	5,583
Total liabilities and stockholders’ equity	$ 12,434	$ 9,325